让科创星火燃成燎原之势

Group 1 - The core idea of the news is the establishment and development of the Nanjing Science and Technology Financial Reform Pilot Zone, which aims to create a demonstration area for science and technology finance, innovative product business aggregation, and deep integration of industry and city [2][3][8] - The pilot zone has seen significant achievements in promoting technology finance from "experiment" to "demonstration," with various financial institutions and enterprises growing together [3][9] - The Nanjing government and financial regulatory bodies have implemented multiple measures to support the pilot zone, including the introduction of specialized financial products and services for technology enterprises [8][14] Group 2 - Nanjing Fangshenghe Pharmaceutical Technology Co., Ltd. has successfully navigated financing challenges by utilizing innovative insurance products, such as the "R&D Expense Loss Insurance," which is the first of its kind in the country [4][5][6] - The company has received nearly 100 million yuan in compensation from insurance, effectively mitigating R&D risks and allowing for further investment in other insurance products [5][6] - Fangshenghe's successful acquisition of Li Tail Pharmaceutical was supported by a nearly 100 million yuan merger loan from Industrial and Commercial Bank of China, facilitated by a new evaluation model for technology enterprises [6][7] Group 3 - The Nanjing pilot zone has established a comprehensive financial service system for technology enterprises, with a focus on "policy + product + model" innovation [9][18] - The introduction of the "investment-loan linkage" model has become a key initiative in promoting technology finance, allowing banks and investment institutions to collaborate effectively [13][17] - By the end of September 2025, the total loan balance for technology enterprises in Nanjing reached 450 billion yuan, marking a 38% year-on-year increase [18]